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A B S T R A C T
To evaluate photodynamic therapy with verteporfin combined with intravitreal bevacizumab in minimally classic
and occult choroidal neovascularization secondary to age-related macular degeneration. 46 eyes of 46 patients (mean age
74.5) included in this prospective, noncomparative, interventional case series. Median follow-up was 24 weeks (12–36).
Verteporfin photodynamic therapy (PDT) was followed by 0.05 mL (1.25 mg) of bevacizumab injected intravitreally
within 24 hours and again after 6 weeks. Whole procedure was repeated in 3-month intervals in case of leakage. Visual
acuity (VA) improved in majority of patients (baseline VA 1.041 log MAR) by mean increase of 1.45 lines (last follow-up)
(p=0.001). Central foveal thickness (CFT) and total macular volume (TMV) decreased by 53 µm (p=0.03) and 1.04 mm3
(p<0.001) respectively. No serious complications were observed.Combined treatment may improve outcome of monothe-
rapy. Significant improvement in VA, CFT and TMA was noted in majority of patients and maintained during fol-
low-up.
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Introduction
Photodynamic therapy with verteporfin is very effec-
tive in patients with classic subfoveal neovascularization
due to age related macular disease.1–3 Also it has shown
positive effect in reducing the risk of visual loss in pa-
tients with occult choroidal neovascularization,4 and in
minimally classic CNV.5 Since we noticed from our own
clinical experience, verteporfin therapy does not produce
too good results in treatment of minimally classic and oc-
cult lesions, as in treatment of classical CNV, the further
investigation for novel approaches in treatment of such
lesion subtypes is fully justified. The positive outcomes of
antiVEGF therapy (e.g.pegaptanib) in treatment of neo-
vascular AMD have been fully reported in several stud-
ies.6,7 Also, there are clinical studies going on to compare
various treatment modalities for neovascular AMD: e.g.
verteporfin vs. pegaptanib. New antiVEGF agent, beva-
cizumab, has also been used in off-label treatment of
neovascular AMD and neovascularization due to patho-
logic myopia for a year now.6,8–10 Bevacizumab, a huma-
nized monoclonal antibody directed against vascular en-
dothelial growth factor, was already approved by Food
and Drug Administration for the treatment of metastatic
colorectal cancer.5,11
Since the pathogenesis of choroidal neovascularization
is multifactorial including both angiogenesis, extravaza-
tion and inflammation, it is fully justified to try to incor-
porate several treatment modalities for combating the dis-
eases. There have been studies suggesting the additive
effect to verteporfin therapy of anti-inflammatory and
anti-angiogenic drugs in treatment of neovascular AMD.12,13
Since the anti-angiogenic effect of triamcinolone adminis-
tered alone is quite weak,14,15 producing only mild tran-
sient effect, and since bevacizumab administered alone
did show promising results in treatment of CNV,6,8–10 it is
quite justified trying to combine verteporfin and intra-
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vitreal bevacizumab as a possibly effective combined
treatment of neovascular AMD. Also photodynamic ther-
apy itself may contribute to additional VEGF expres-
sion,16 therefore further additive effect may be proposed.
In this study we focused on minimally classic and oc-
cult membranes, as those in clinical practice present
main challenge, and according to our own clinical find-
ings, do not respond that well to photodynamic therapy
alone or when combined with intravitreal triamcinolone.
So in this study we aimed at providing preliminary effi-
cacy and safety results to help determine whether com-
bined verteporfin and bevacizumab treatment can im-
prove visual acuity and macular morphology parameters
such as thickness and volume in patients with neovascu-
lar AMD.
Methods
There were 46 eyes of 46 patients included in this pro-
spective, interventional, noncomparative case series. Pa-
tients were recruited by our retinal subdivision and were
required to meet inclusion criteria. At baseline, all pa-
tients underwent VA measurement using EDTRs chart,
slit lamp and fundus examination and IOP measure-
ments. Fluorescein angiography was performed to iden-
tify lesion subtype and location and to verify active
choroidal neovascular leakage. Also OCT scan was per-
formed to verify exudation, and to measure fovel thick-
ness and macular volume. Inclusion criteria were as fol-
lows: patient age  50, VA better or equal to 20/400, active
leakage at FA and OCT scan, subfoveal lesion location,
GDL of  7500 µm, no previous treatment. This study
complied with the and has been approved by the Ethics
Committee of the Eye Clinic, and written informed con-
sent was obtained from the patients in the study describ-
ing the experimental nature of the bevacizumab off-label
use and potential risks.
Photodynamic therapy with verteporfin (Visudyne,
Novartris Ophthalmics, Basel, Switzerland) was perform-
ed according to the recommended standard procedure.1,2
Following PDT, within a mean of 24 hours (20–28 h), pa-
tients received topical and subconjunctival anesthesia.
1.25 mg of bevacizumab (Avastin 100 mg / 4 mL vial, Ge-
nantech Inc, San Francisco, USA) in a volume of 0.05 mL
solution, was administered intravitreally through pars
plana by 27-gauge needle. The injection was given in the
operating room under the operating microscope, after the
povidone-iodine eye cleansing. No paracenthesis was re-
quired due to small volume injected. An additional in-
travitreal application of bevacizumab was performed in a
6 weeks interval using the protocol already described.
Patients were asked to come back for follow-up visits
in 12-week (post-PDT) intervals, when similar ophthal-
mologic examination was performed including VA mea-
surement, IOP measurement, angiography and OCT
scan. In case of active leakage presence at the 12-week
follow-up visits, the already described combined regimen
of verteporfin PDT and 2 bevacizumab intravitreal appli-
cations was carried out.
The main outcome measures were a mean change in
VA between baseline and last follow-up, measured using
EDTRS chart, a mean change in central foveal thickness
(CFT) and total macular volume (TMV) (within 3000 µm
radius from center of fovea) at baseline and last fol-
low-up, measured by OCT. The mean VA, foveal thick-
ness and macular volume at the final follow-up were then
compared with the baseline values, and statistically ana-
lyzed using paired t test to determining statistical signifi-
cance between two corresponding groups.
Results
A total of 46 eyes of 46 patients with choroidal neo-
vascularization due to AMD were included in the study,
meeting the inclusion criteria described previously.
There were 29 females and 17 males, with a mean age of
74.5 years (range 60–84). The mean lesion size was 3889
µm (range 700–7700). There were 36 minimally classic
CNV subtypes and 10 occult CNV subtypes as docu-
mented angiographicaly and by OCT scan. Both lesion
subtypes responded with a reduction in leakage, as eval-
uated by an experienced retinologist. Median follow-up
was 24 weeks (12–36). The mean VA at baseline was
20/200–2 (1.041 logMAR), the mean central foveal thick-
ness (CFT) was 384 µm, while the mean total macular
volume (TMV) was 9.39 mm3. There was a significant
mean increase in VA from baseline to the time of last fol-
low-up visit of 1.45 lines (p=0.001) (Fig. 1). The patients
with minimally classic subtype had a mean increase of
1.53 (p<0.001) while patients with occult CNV had a
mean increase in VA of 1.37 lines (p=0.01).
Furthermore there was a significant mean decrease in
CFT from baseline (384 µm) to the time of last follow-up
visit of 53 µm (p=0.03). Patients with minimally classic
membranes responded with even greater foveal thick-
ness reduction than patients with occult membranes, 67
µm (p=0.01), 49 um (p=0.04) respectively (Fig. 2). The
mean macular volume at last follow-up decreased signifi-
cantly for 1.04 mm3 (p<0.001) compared to baseline
(9.39 mm3) (Fig. 3).
Thirty nine patients (84.8 %) required only one com-
bined treatment to achieve resolution of leakage, while 6
(13%) patients needed an additional combined treatment
to resolve the leakage. Only 1 patient (2.1%) needed a
third treatment regimen, but only a reduction of leakage
was achieved in this case. So the mean number of com-
bined regimen treatments was 1.15 for the eye. In mini-
mally classic subtype 6 patients needed an additional
treatment, compared to 1 patient in occult subtype group.
When treatment results were analyzed with respect
to lesion size, lesions larger that 5000 µm maintained
stable vision, but improvement in VA was not statisti-
cally significant. On the other hand, those lesions show-
ed significant macular volume decrease, which effect was
maintained to the last follow-up visit.
There were no adverse reactions to the combined
treatment regimen. Neither inflammation nor infection
was observed. No patients required topical anti-glauco-
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matous therapy, other than what they used previously
for their preexisting glaucoma. No patient complained of
significant vision blurring after bevacizumab injection
and blurring resolved usually within few days. No major
cataract progression was noted and only 2 patients un-
derwent cataract extraction.
Discussion
We are not aware of any study combining intravitreal
bevacizumab with verteporfin PDT in treatment of mini-
mally classic and occult choroidal neovascularization sec-
ondary to AMD. As a matter of fact, there are only few
studies evaluating efficiency of intravitreal bevacizumab
given as monotherapy in treatment of exudative AMD.6,8,10
Since those studies clearly show significant improvement
in visual acuity outcome, and since our own clinical expe-
rience confirms those finding, we tried to combine a regi-
men that would address our biggest clinical concern:
minimally classic and occult subtype of the lesion. Even
verteporfin studies1–4 suggest that in the majority of pa-
tients with such subtypes of lesions, stabilization of vi-
sual acuity, rather than improvement can be expected.
The probable reason for such an outcome can be ex-
plained by more difficult light activation of the drug ab-
sorbed by target tissue. Minimally classic and occult
membranes are located more deeply than classical mem-
branes and their exposure to the light is somewhat
blocked by blood, exudates and partially intact retinal
pigment epithelium above them. In such lesions anti-
VEGF substance may have better access to target struc-
ture by diffusion. It has been recently shown that al-
though having a full length antibody structure, beva-
cizumab can penetrate full thickness retina.17 On the
other hand, the classical component of the minimally
classic lesion may already be fully established and hard
to respond completely to the pharmacological treatment
alone. Therefore, the rationale of combining two treat-
ments is evident as they may be acting more synergisti-
cally in resolving the activity of the lesions. Since the
half-life of bevacizumab is quite long,18 we though it
would be appropriate to give bevacizumab in 6 weeks in-
tervals as we do in monotherapy and reevaluate the
treatment effect after 3 months following verteporfin
PDT administration since repeated PDT treatment could
be given every 3 months.
Also there have already been several clinical stu-
dies12–15 showing the synergistic positive effect of verte-
profin and intravitreal triamcinolone when used in com-
bination treatment of choroidal neovascularization due
to AMD. Although the visual outcome after such combi-
nation treatment is significantly better when compared
to baseline, it is even more of a benefit to have a reduced
number of retreatments required to maintain such a re-
sult, for what effect additive role of triamcinolone has
been suggested. When triamcinolone is given as mono-
therapy no significant and lasting improvement of visual
acuity is achieved19. Since bevacizumab showed a clear
effect of its own in improving visual outcome when given
as monotherapy,6 it was our hypothesis that we could
document an even greater visual acuity improvement if
we would combine it with PDT. As the results of the
verteporfin monotherapy1–3 are so evident in classic le-
sion subtype, we thought it would be easier to evaluate
additive effect of bevacizumab in a subgroup of lesions
not so responsive to verteporfin monotherapy.4 It is even
our impression from our own clinical experience that
large minimally classic membranes respond better to
intravitreal bevacizumab rather than verteporfin PDT,
so we even recommend to our patients intravitreal beva-















Figure 1. There was a significant mean increase in best corrected
visual acuity from baseline to the time of last follow-up visit of






























Figure 2. There was a significant mean decrease in central foveal
thickness from baseline to the time of last follow-up visit of 53 µm
(p=0.03). Patients with minimally classic membranes responded
with even greater foveal thickness reduction than patients with


















Figure 3. The mean macular volume at last follow-up decreased
significantly for 1.04 mm3 (p<0.001) compared to baseline (9.39
mm3).
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cizumab over PDT in such lesions. The only difference
we have noticed from our clinical practice, compared to
this study, was in administration of bevacizumab when
given as monotherapy. Several, (up to 6) intravitreal
bevacizumab applications were usually needed to resolve
the leakage if bevacizumab was given non-combined with
PDT in treatment of such lesions.
The proposed dose of the intravitreal bevacizumab is
very small of 1.25 mg (0.05 mL), and we have not experi-
enced any problems with intraocular pressure raise.
There is always a risk of endophthalmitis, but since no
paracenthesis was needed to control the eye pressure,
the risk would have been even smaller. Also, the post-ap-
plication time was well tolerated by patients, when com-
pared to intravitreal triamcinolone, as bevacizumab is a
clear solution, not responsible for vitreal staining.
Even in these subtypes (minimally classic and occult)
of choroidal neovascularization due to AMD, we could
isolate a subgroup of lesions of size smaller than 5000
µm, responding better to the treatment regimen, what
reiterates the importance of early detection and early
treatment initiation. This observation clearly shows the
combined regimen acts as strong suppressant to cho-
roidal neovascularization, but the damage occurring to
the photoreceptor layer becomes irreversible with longer
duration of the disease.
We find our study to be a pivotal study in evaluation
of treatment results of combined verteporfin and bevaci-
zumab, and further studies including more participants
are needed to confirm our finding. Limitations of this
study are clearly its interventional character, noncom-
parative nature and variability in follow-up. But the in-
formation provided could be used to design subsequent
comparative prospective studies.
Regardless of whether bevacizumab survives the ar-
rival of newer hopefully more potent antiVEGF inhibi-
tors, some already in phase III of clinical trials, we are
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Figure 4. Before therapy a large minimally classic lesion shown
on OCT scan before therapy (A), and 3 months after second treat-
ment. Central foveal thickness decreased for 136 µm, while total
macular volume decreased for 4.46 mm3, as is graphically shown
by computer analysis (C, D). After 2 combination treatments vi-
sual acuity increased from 20/400 to 20/200 over 6 moths.
Figure 5. Before therapy a small lesion with subretinal exuda-
tion just beneath fovea as shown on OCT scan (A), and 3 months
after treatment with complete resolution of subretinal fluid. Cen-
tral foveal thickness decreased for 10 µm, while total macular
volume decreased for 0.6 mm3. After combination treatment, vi-
sual acuity increased from 20/100 to 20/40 over 3 moths.
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sure that the main idea of this combination concept can
be extrapolated to the newer antiVEGF substances, in
case their prove more efficient than bevacizumab. But
for now, we have a very limited pool of agents we can
choose from in pharmacological treatment of exudative
AMD.
As the need for more effective treatment regimen for
neovascular AMD is growing, and the number of possible
tools is getting wider, we may see more and more studies
combining not only two therapeutic options, but rather 3
or even more. We may see maybe a combination of sev-
eral pharmacological approaches, including antiVEGF,
anti-inflammatory (triamcinolone) and verteporfin PDT.
The rational is there as the complexity of pathophy-
siology of exudative AMD is evident.
So our results, showing improvement not only in vi-
sual acuity but also in macular morphological indices in
minimally classic and occult lesions, are clearly consis-
tent with our hypothesis that in future, the treatment
modalities for exudative AMD will involve combined ap-
proaches, at least for some time.
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FOTODINAMSKA TERAPIJA KOMBINIRANA SA INTRAVITREALNIM BEVACIZUMABOM U
LIJE^ENJU KOROIDALNE NEOVASKULARIZACIJE U SKLOPU SENILNE MAKULARNE
DEGENERACIJE
S A @ E T A K
Istra`iti u~inkovitost fotodinamske terapije verteporfinom kombinirane sa intravitrealnim bevacizumabom u lije-
~enju minimalno klasi~ne i oklutne koroidalne neovaskularizacije u sklopu senilne makularne degeneracije.46 o~iju
46-tero pacijenata (prosje~na dob 74.5) u prospektivnoj, nekomparativnoj, intervencijskoj seriji pre}enih tijekom me-
diana od 24 tjedna (3–32). Fotodinamska terapija verteporfinom kombinirana je sa intravitrealno primjenjenih 0.05 mL
(1.25 mg) bevacizumaba unutar 24 h te ponovo nakon 6 tjedana. Cijeli kombinirani postupak ponavljan je u tromje-
se~nim intervalima u slu~aju eksudacije. Vidna o{trina (VA) pobolj{ana je u ve}ine pacijenata (po~etna VA 1.041 log
MAR) za 1.45 liniju (zadnja kontrola) (p=0.001). Sredi{nja fovealna debljina (CFT) i ukupni makularni volumen (TMV)
smanjen je za 53µm (p=0.03) i 1.04 mm3 (p<0.001). Zna~ajne komplikacije nisu zabilje`ene. Kombinirani pristup mo`e
pobolj{ati ishod lije~enja. Zna~ajno pobolj{anje VA, CFT i TMA je zabilje`eno u ve}ine pacijenata i odr`avano tijekom
pra}enja.
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